Sinopharm Group Co. Ltd. (SHTDF) Stock Price & Analysis
Sinopharm Group Co. Ltd. (SHTDF) — price $1.94 (+0.67%), as of the Oct 6, 2026 trading session; market cap $6.05B.
Educational signal · not a buy or sell recommendation · How to read this
Sinopharm Group Co. Ltd. · SHTDF
Sinopharm Group Co. Ltd. is a major Chinese healthcare company primarily involved in the wholesale and retail distribution of pharmaceuticals, medical equipment, and health products. It operates through extensive distribution networks, a large retail pharmacy chain, and other business segments including manufacturing and IT development.
Price as of Oct 6, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.94 | |
| Change on the day | +0.67% | |
| 52-week range | $1.72 – $2.70 | |
| Market capitalisation | $6.05B | |
| Price / earnings (trailing) | 5.66 | |
| Shares traded on the day | 1.6K |
Price & events
Other perspectives
Council score for Sinopharm Group Co. (SHTDF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
2 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the SHTDF film — every key number, told as a short cinematic story
~2 min · open the film
What is Sinopharm Group Co. (SHTDF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Sinopharm Group Co. Ltd. (SHTDF) is the company analyzed here. It employs 94,910 people and is led by Wanyong Lian. In Q2 FY2026 it reported revenue of $41.69B and net income of $502M. The market values it at $6.05B.
What do the latest results show for Sinopharm Group Co. (SHTDF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $41.69B. Against analyst estimates the company has EPS beat 2 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $41.69B | $502M | $0.16 (diluted) |
| Q4 FY2025 | $42.49B | $542M | $0.18 (diluted) |
| Q2 FY2025 | $42.75B | $517M | $0.17 (diluted) |
| Q4 FY2024 | $43.30B | $500M | $0.16 (diluted) |
What are the financial strengths and risks for Sinopharm Group Co. (SHTDF)?
Short answer
The distress and quality screens read Altman Z 3.70 · Piotroski F 7. Trailing ratios: ROE 8.3% · ROA 1.7% · current ratio 1.40 · earnings yield 17.8% · free-cash-flow yield 47.1%.
Sinopharm Group Co. Stock: Key Questions Answered
These answers are editorial: 2 of these 8 answers are drawn from the SHTDF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 6 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SHTDF a good stock to buy?
Stock Expert AI does not rate SHTDF buy, sell or hold. Sinopharm Group Co. Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SHTDF stock price today?
The last price recorded on this page for Sinopharm Group Co. Ltd. (SHTDF) is $1.94, as of the Oct 6, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the implications of Sinopharm Group Co. Ltd.'s OTC Other listing for investors?
Sinopharm Group Co. Ltd.'s listing on the OTC Other tier carries several implications for investors. This tier typically has less stringent disclosure requirements compared to major exchanges like NYSE or NASDAQ, and even higher OTC tiers, leading to an "Unknown" disclosure status for SHTDF.
What strategic partnerships does Sinopharm Group Co. Ltd. have and how do they contribute to its operations?
Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab, a collaboration designed to enhance its commercial reach and market transformation efforts.
What are the key factors to evaluate for SHTDF?
Evaluate SHTDF on fundamentals, analyst consensus, and risk factors. P/E: 5.66x. **Enhanced Pharmaceutical Distribution and Logistics:** The company's core Pharmaceutical Distribution unit, which supplies hospitals, clinics, and other distributors, can capitalize on the increasing volume and complexity of pharmaceutical products entering the Chinese market. Not financial advice.
How frequently does SHTDF data refresh on this page?
SHTDF's price is the last quote we recorded, from the Oct 6, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SHTDF's recent stock price performance?
Sinopharm Group Co. Ltd. (SHTDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established and dominant market position within the Chinese healthcare sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHTDF overvalued or undervalued right now?
Sinopharm Group Co. Ltd. (SHTDF) trades at 5.66x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.94 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T17:25:22.507Z. | |
px.change | Change on the day | +0.67% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $6.05B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-06. FMP quote timestamp: 2026-10-06T16:21:10.000Z. Captured from FMP at 2026-10-06T17:25:13.059Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.01285 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 5.66 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.6K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $41.69B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $502M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $1.72 – $2.70 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.employees | Employees | 94,910 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.ceo | Chief executive | Wanyong Lian | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-01 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.70 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 8.3% · ROA 1.7% · current ratio 1.40 · earnings yield 17.8% · free-cash-flow yield 47.1% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.